_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
It has been built at a cost of Rs 19.5 crores through internal accruals of the Malabar Institute of Medical Sciences (MIMS)
This low-cost and highly reliable technology will help in increasing testing in rural and tribal areas
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
This clinical study demonstrated that the 14-day regimen of ImmunoSEB and ProbioSEB CSC3 resolved post-Covid-19 fatigue symptoms and improved patients' functional status and quality of life
Crosscope and KFBIO join forces to lead digital transformation for pathology in India and emerging markets
The tracker gives week by week coverage of the first and second dose of vaccine and also their effectiveness
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Subscribe To Our Newsletter & Stay Updated
